3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Status
Completed
3
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Endocrine
3
NET
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
29
Carcinoma, Transitional Cell
25
Urinary Bladder Neoplasms
24
Neoplasms
22
Carcinoma, Merkel Cell
20
Neoplasm Metastasis
18
Carcinoma, Renal Cell
17
Colorectal Neoplasms
16
Breast Neoplasms
16
Squamous Cell Carcinoma of Head and Neck
15
Ovarian Neoplasms
14
Triple Negative Breast Neoplasms
11
Pancreatic Neoplasms
9
Melanoma
9
Head and Neck Neoplasms
8
Stomach Neoplasms
7
Recurrence
6
Carcinoma, Hepatocellular
6
Ureteral Neoplasms
5
Small Cell Lung Carcinoma
5
Prostatic Neoplasms
5
Urethral Neoplasms
4
Sarcoma
4
Neuroendocrine Tumors
4
Leukemia, Myeloid, Acute
4
Glioblastoma
4
Carcinoma, Squamous Cell
4
Uterine Cervical Neoplasms
3
Turcot syndrome
3
Skin Neoplasms
3
Interventions
Cisplatin
12
Everolimus
10
Nivolumab
8
Etoposide
8
Temozolomide
6
Carboplatin
6
atezolizumab
5
Irinotecan
5
Ipilimumab
5
Fluorouracil
5
Bevacizumab
5
pembrolizumab
4
lutetium Lu 177 dotatate
4
Capecitabine
4
avelumab
3
Paclitaxel
3
IFL protocol
3
surufatinib
2
sintilimab
2
dostarlimab
2
cabozantinib
2
belinostat
2
azaspirane
2
Topotecan
2
Radiosurgery
2
Positron Emission Tomography Computed Tomography
2
PE regimen
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Magnetic Resonance Imaging
2
Leucovorin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Neuroendocrine
×
avelumab
×
Clear all
NCT03352934
2022-02-25
AveNEC
Johannes Gutenberg University Mainz
Phase 2
Completed
60 enrolled
NCT03278405
2020-03-18
NET-001
Sunnybrook Health Sciences Centre
Phase 1/2
Completed
10 enrolled
NCT03147404
2019-12-30
MS100070-0177
Samsung Medical Center
Phase 2
Completed
14 enrolled